Back to top
more

Immunomedics, Inc. (IMMU)

(Delayed Data from NSDQ)

$14.74 USD

14.74
2,889,678

-0.16 (-1.07%)

Updated May 3, 2019 04:00 PM ET

After-Market: $14.75 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

Immunomedics Up as Breast Cancer Drug Study Shows Efficacy

Immunomedics (IMMU) soars as the phase III study on breast cancer drug shows efficacy and will be subsequently halted.

Immunomedics (IMMU) in Focus: Stock Moves 5% Higher

Immunomedics (IMMU) saw a big move last session, as its shares jumped nearly 5% on the day, amid huge volumes.

Why Is Immunomedics (IMMU) Down 18% Since Last Earnings Report?

Immunomedics (IMMU) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Options Traders Expect Huge Moves in Immunomedics (IMMU) Stock

Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.

Immunomedics (IMMU) Reports Wider-Than-Expected Q4 Loss

Immunomedics (IMMU) posts wider-than-expected Q4 loss. Its BLA seeking accelerated approval for sacituzumab govitecan in metastatic triple-negative breast cancer (mTNBC) is accepted for filing by FDA.

Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?

Investors are looking forward to Cabometyx's performance and pipeline updates, when Exelixis (EXEL) reports Q4 results.

What Awaits Jazz Pharmaceuticals (JAZZ) in Q4 Earnings?

Progress of its pipeline candidates and launch of Sunosi is likely to have increased Jazz Pharmaceuticals (JAZZ) operating expenses in the fourth quarter. Xyrem likely to have continued strong demand trend.

Why Earnings Season Could Be Great for Immunomedics (IMMU)

Immunomedics (IMMU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

What's in Store for Jounce (JNCE) This Earnings Season?

Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results.

What Awaits Spectrum Pharmaceuticals (SPPI) in Q4 Earnings?

Progress of its pipeline candidates is likely to have increased Spectrum Pharmaceuticals' (SPPI) operating expenses in the fourth quarter.

    What's in Store for Aimmune (AIMT) This Earnings Season?

    Aimmune (AIMT) is likely to provide an update on Palforzia's launch plans during Q4 investors' call. The drug gets an approval in January 2020 for the treatment of peanut allergy.

    Is a Beat in the Cards for Clovis' (CLVS) Earnings in Q4?

    Clovis' (CLVS) sole marketed drug, Rubraca, is likely to have driven revenues in the fourth quarter.

    What's in Store for Corcept (CORT) This Earnings Season?

    During Corcept's (CORT) Q4 earnings call, investor focus will be on the sales uptake of its Cushing's syndrome drug Korlym and other pipeline updates.

    What Awaits Intra-Cellular Therapies (ITCI) in Q4 Earnings?

    Intra-Cellular Therapies (ITCI) is likely to provide update on its commercialization plan for Caplyta, approved for treating schizophrenia in December 2019, on the Q4 call.

    Mylan (MYL) to Report Q4 Earnings: What's in the Offing?

    Investors will look forward to regular top and bottom-line numbers and updates on merger with Upjohn, when Mylan (MYL) reports Q4 results.

    5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates

    Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

    Incyte (INCY) to Report Q4 Earnings: What's in the Cards?

    Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports fourth-quarter 2019 results.

    Immunomedics Sees Hammer Chart Pattern: Time to Buy?

    Immunomedics has been struggling lately, but the selling pressure may be coming to an end soon.

    FDA Accepts Immunomedics' BLA Refiling for Breast Cancer Drug

    The FDA accepts Immunomedics' (IMMU) BLA resubmission for sacituzumab govitecan to treat patients with metastatic triple-negative breast cancer, having received at least two prior therapies.

    Company News For Dec 27, 2019

    Companies In The News Are: QGEN, IMMU, CANF, SBPH

    Kinjel Shah headshot

    4 Drug/Biotech Outperformers That May Lose Steam in 2020

    Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

    Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?

    Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.

    Immunomedics Resubmits Application for Breast Cancer Drug

    Immunomedics (IMMU) resubmits BLA to the FDA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer, who have received at least two prior therapies.

    Implied Volatility Surging for Immunomedics (IMMU) Stock Options

    Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.